Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis

被引：0

作者：

Singer, Barry A. ^{[1
]}

Shafer, S. James ^{[2
]}

Arnold, Douglas L. ^{[3
,4
]}

Bowen, James D. ^{[5
]}

LaGanke, Christopher ^{[6
]}

Chen, Hailu ^{[7
]}

Hanna, Jerome ^{[7
]}

Miller, Catherine ^{[7
]}

Leigh-Pemberton, Richard ^{[8
]}

Naismith, Robert T. ^{[9
]}

机构：

[1] Missouri Baptist Med Ctr, MS Ctr Innovat Care, St Louis, MO USA

[2] Vero Beach Neurol & Res Inst, Vero Beach, FL USA

[3] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[4] NeuroRx Inc, Wilmington, DE USA

[5] Swedish Neurosci Inst, Multiple Sclerosis Ctr, Seattle, WA USA

[6] North Cent Neurol Associates, Cullman, AL USA

[7] Biogen, Cambridge, MA USA

[8] Alkermes Inc, Dublin, Ireland

[9] Washington Univ, Sch Med, St Louis, MO 14263 USA

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1337

引用

页数：4

共 50 条

[1] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
Naismith, R. T.
Badwan, R.
Chen, H.
Lyons, J.
Miller, C.
Scaramozza, M.
Shankar, S. L.
Antezana, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 587 - 588
[2] Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
Bomprezzi, Roberto
[J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 20 - 30
[3] Tolerability of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis Patients with Gastrointestinal Comorbidities at Baseline
Singer, B. A.
Wray, S.
Ziemssen, T.
Wundes, A.
Jasinska, E.
Chen, H.
Lewin, J. B.
Lyons, J.
Messer, J.
Scaramozza, M.
Naismith, R. T.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 39 - 39
[4] Oral fumarate for relapsing-remitting multiple sclerosis
Sorensen, Per Soelberg
Sellebjerg, Finn
[J]. LANCET, 2008, 372 (9648): : 1447 - 1448
[5] Real world experience with dimethyl fumarate in relapsing-remitting multiple sclerosis
Cox, S. R.
Jordan, S.
Sharma, D.
O'Boyle, G.
Tubridy, N.
Hutchinson, M.
Mcguigan, C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 614 - 615
[6] Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis
Sattarnezhad, Neda
Healy, Brian C.
Baharnoori, Moogeh
Diaz-Cruz, Camilo
Stankiewicz, James
Weiner, Howard L.
Chitnis, Tanuja
[J]. NEUROLOGY, 2017, 88
[7] Dimethyl fumarate: A guide to its use in relapsing-remitting multiple sclerosis
Keating G.M.
Burness C.B.
Deeks E.D.
[J]. Drugs & Therapy Perspectives, 2014, 30 (9) : 303 - 308
[8] Early versus delayed initiation of fingolimod or dimethyl fumarate in relapsing-remitting multiple sclerosis
Lorscheider, J.
Schadelin, S.
Benkert, P.
Lienert, C.
Hanni, P.
Derfuss, T.
Decard, B.
Kuhle, J.
Kappos, L.
Yaldizli, O.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 257 - 258
[9] Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis
Lorscheider, Johannes
Benkert, Pascal
Lienert, Carmen
Haenni, Peter
Derfuss, Tobias
Kuhle, Jens
Kappos, Ludwig
Yaldizli, Oezguer
[J]. JOURNAL OF NEUROLOGY, 2021, 268 (03) : 941 - 949
[10] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
Muller, Jannis
Schadelin, Sabine
Lorscheider, Johannes
Benkert, Pascal
Hanni, Peter
Schmid, Jurg
Kuhle, Jens
Derfuss, Tobias
Granziera, Cristina
Yaldizli, Ozgur
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818

← 1 2 3 4 5 →